

031404

16569 U.S. PTO

PTO/SB/05 (01-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

First Inventor

Title

Express Mail Label No.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 33]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 6]
5. Oath or Declaration [Total Sheets]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ Paper
 - c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement of Power of Attorney (when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☒ Continuation-in-part (CIP)

of prior application No.: 60/455,003
60/455,003

Prior application information: Examiner ? Art Unit: ?
For CONTINUATION OR DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☐ Customer Number:

OR ☒ Correspondence address below

Name	Christopher Rudd, Immune Ventures Corp.				
Address	39E Bellis Circle				
City	Cambridge	State	MA	Zip Code	02140
Country	USA	Telephone	617-864-5251	Fax	

Name (Print/Type)	Registration No. (Attorney/Agent)	
Signature		Date

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

17354 U.S. PTO
10/800985

031404

16569
031404
U.S. PTO

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)

Complete if Known

Application Number 60/455,003
Filing Date 03/14/2004
First Named Inventor Rudd
Examiner Name
Art Unit
Attorney Docket No.

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account:

Deposit Account Number
Deposit Account Name

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments

☐ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	385
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)			(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple Dependent	-3** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater. For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee (\$)	Fee Code (\$)	Fee (\$)	Fee Description	Fee Paid
1051 130	2051 65	1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	2053 130	1053 130	2053 130	Non-English specification	
1812 2,520	2054 2,520	1812 2,520	2054 2,520	For filing a request for ex parte reexamination	
1804 920*	2055 920*	1804 920*	2055 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	2056 1,840*	1805 1,840*	2056 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	1403 290	2403 145	Request for oral hearing	
1451 1,510	2451 1,510	1451 1,510	2451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	1502 480	2502 240	Design issue fee	
1503 640	2503 320	1503 640	2503 320	Plant issue fee	
1460 130	2460 130	1460 130	2460 130	Petitions to the Commissioner	
1807 50	2807 50	1807 50	2807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	2806 180	1806 180	2806 180	Submission of Information Disclosure Stmt	
8021 40	2801 40	8021 40	2801 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	2802 900	1802 900	2802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type) Christopher Rudd

Signature

Registration No.
(Attorney/Agent)

(Complete if applicable)

Telephone 617-864-5251

Date March 14, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IMMUNE VENTURES

Immune Ventures
39E Bellis Circle
Cambridge, MA 02140

Telephone (617 864-5251)

March 14, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria
VA 22313-1450

Dear Sir/Madam

Please find enclosed the patent application entitled "Use Inhibitors of Glycogen Synthase-3 to augment CD28 dependent T-cell responses". The application is an extension of a provisional application that was submitted on March 14, 2003 (#60,455,003). Please also find enclosed the Declaration for Utility or Design Patent Application (PTO/SB/01), Declaration (PTO/SB/01), Utility Patent Application Transmittal form (PTO/SB/05), Fee Transmittal for FY 2004 (PTO/SB/17) as well as the check for \$385, and a postal return card. From conversations with your office, I believe that these are the basic forms needed for the registration of the patent. If there is a form that is missing I would be pleased to submit it ASAP.

Thank you for your assistance with this.

Sincerely,

Christopher Rudd
Immune Ventures



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
60/455,003	03/14/2003		80		6		

CONFIRMATION NO. 2219

Immune Ventures
39E Bellis Circle
Cambridge, MA 02140

FILING RECEIPT



OC000000010066213

Date Mailed: 05/19/2003

Receipt is acknowledged of this provisional Patent Application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Christopher E. Rudd, Cambridge, MA;

If Required, Foreign Filing License Granted: 05/19/2003

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Use of inhibitors of glycogen synthase kinase 3 to augment CD28 dependent T-cell responses

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING

BEST AVAILABLE COPY



DR. CHRISTOPHER E. RUDD
PH. 617-864-5251
39E BELLIS CIR.
CAMBRIDGE, MA 02140

5-13/110
0003292789

2934

Dec. 13, 2004
DATE:

PAY TO THE
ORDER OF

US Patent & Trademark Office — \$ 385.00
— three hundred and eighty-five — DOLLARS



81336 www.fleet.com
Longwood Avenue Office
Boston, Massachusetts 02115

[Signature]

MEMO

⑆011000138⑆ 00032 92789⑈ 2934

ESTATE

CHRISTOPHER RUDD
IMMUNE VENTURES CORP
39E BELLIS CIRCLE
CAMBRIDGE, MASS
02140

